Article Text

Download PDFPDF
Need to individualise cholesterol-lowering therapy
  1. Dieter Lütjohann1,
  2. Oliver Weingärtner2
  1. 1 Institute for Clinical Chemistry and Clinical Pharmacology, University Clinics Bonn, Universitätsklinikum Bonn, Bonn, Nordrhein-Westfalen, Germany
  2. 2 Klinik für Innere Medizin I, Universitätsklinikum Jena, Jena, Germany
  1. Correspondence to Professor Oliver Weingärtner, Klinik für Innere Medizin I, Universitätsklinikum Jena, Friedrich-Schiller-Universität Jena, Jena 07747, Germany; oliver.weingaertner{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

To the Editor,

We read with great interest the excellent study by Akyea and colleagues who reported that more than 50% of the patients in a prospective cohort study of primary care exhibit suboptimal low-densitycholesterol-lowering on statin treatment. …

View Full Text


  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; internally peer reviewed.

  • Patient consent for publication Not required.

Linked Articles